title: Pharmacokinetics of pirazolac, a new anti-inflammatory drug, in human volunteers. III. Steady state plasma levels.
abstract: Seven male, young subjects received twice daily 300 mg of pirazolac (PAA) for one week and twice daily 600 mg PAA for a further week as tablet. Plasma levels of PAA were monitored every day just before dosing and up to 72 hours after the last dose using a specific HPLC-method. During the first week of treatment trough steady state levels of Cssmin = 24 +/- 8 micrograms/ml were reached at day 4. After changing of dose regimen to twice daily 600 mg a new steady was established four days later with Cssmin = 62 +/- 15 micrograms/ml. PAA in the plasma was highly (99.2 +/- 0.8%) bound to plasma proteins. Time course of the decay of PAA levels in the plasma after the last dose was similar to that after a single administration.
authors.affiliation: Research Laboratories, Schering AG, Berlin, FRG.
authors.forename: U
authors.initials: U
authors.lastname: Täuber
authors.forename: R O
authors.initials: RO
authors.lastname: Beiersdorff
authors.forename: H
authors.initials: H
authors.lastname: Matthes
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000097:blood*; D001798:Blood Proteins / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006207:Half-Life; D006801:Humans; D008297:Male; D011485:Protein Binding; D011720:Pyrazoles / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001798:Blood Proteins; D011720:Pyrazoles; C046317:pirazolac